• Read more about The new therapeutic imperative in cancer management: Sequence, biosimulate, treat.

• Read more about Cellworks’ Computational Biosimulation Lab Secures CLIA Certification to Advance Personalized Therapy Decision Support

CLIA Certification Broadens Cellworks’ Capabilities to Deliver Personalized Therapy Predictions that Improve Cancer Treatment Outcomes

• Read more about Cellworks Enhances TRI with Personalized Tumor Microenvironment Modeling to Predict Overall Survival in NSCLC Patients Receiving Immunotherapy

Study Introduces a Personalized Method of Predicting Immunotherapy Response in NSCLC Patients and Reveals Specific Immune Markers Correlated with Improved Outcomes

• Read more about Are IDH Mutations a Predictor of Venetoclax Response?
• Add new comment

Data from a small clinical trial of venetoclax in acute myeloid leukemia (AML) supported an FDA breakthrough therapy designation for use in combination with hypomethylating agents in treatment-naïve patients who are ineligible for high-dose induction chemotherapy (PMID: 31628431).  Approval of BCL-2 inhibitors raises the question of the mechanism of action in AML and patient selection for treatment. Unfortunately, no biomarkers or methods exist to predict venetoclax response in AML, making treatment selection challenging.

• Read more about Cellworks Biosimulation Combined with Tumor Microenvironment Modeling Enhances Predictions of IO Response in NSCLC Patients

Study finds utilizing genomic and transcriptomic data with biosimulation enhances personalized predictions of IO response in NSCLC

• Read more about Cellworks Biosimulation Predicts PARPi Benefit in Patients with Ovarian, Pancreatic, Prostate and Triple-Negative Breast Cancers

Personalized Therapy Biosimulation Study Identifies Homologous Recombination Deficiency in Cancer Patients Beyond BRCA Status

• Read more about Cellworks Biosimulation Identifies which NSCLC Patients will Benefit from Combining Chemotherapy with Immunotherapy

• Read more about Cellworks Biosimulation Identifies which NSCLC Patients will Benefit from Combining Chemotherapy with Immunotherapy

New study validates Cellworks predictions of chemotherapy benefits in real-world NSCLC patients, guiding treatment decisions beyond PD-L1 status

• Read more about Cellworks Biosimulation Predicts Chemotherapy Benefit in Osimertinib-treated NSCLC Patients with EGFR Mutations

Study Uncovers Biomarkers Linked to Chemotherapy Response in NSCLC Patients Carrying EGFR Variants

• Read more about Cellworks Aims to Validate Clinical Decision Support Capabilities of Computational Model